pokerstakes|75%癌症患者肿瘤完全消失！CG Oncology(CGON.US)免疫疗法3期临床结果积极

CG Oncology (CGONPokerstakes.us) the company announcedPokerstakesIt achieved positive results in the study of oncolytic virus therapy cretostimogene and in phase 3 clinical trials in patients with high-risk non-muscular invasive bladder cancer (NMIBC) who did not respond to BCG (BCG). 75.2% (79max 105) of the patients achieved complete remission. In addition, 29 patients maintained complete remission for more than 12 months. This treatment has been granted breakthrough therapy recognition and fast-track qualification by FDA in the United States.

It is reported that Cretostimogene is an oncolytic virus immunotherapy for intravesical administration, which is similar to that of BCG. It is based on a modified adenovirus type 5 (Ad5) skeleton, contains a tumor-specific promoter and carries a transgene expressing granulocyte-macrophage colony-stimulating factor (GM-CSF). This design allows cretostimogene to be selectively expressed in tumor cells and, after lysis, releases GM-CSF along with tumor-specific antigens and other danger signals. GM-CSF can activate dendritic cells (DC). DC cells recognize tumor antigens and present them to cytotoxic and helper T cells to promote their maturation. These T cells can then circulate throughout the body, identifying and attacking residual tumor cells.

CG Oncology, the first biotech company to complete IPO in 2024, raised $380 million through IPO in January this year. The company's oncolytic virus therapy cretostimogene is currently being tested in three clinical trials.